一品红(300723.SZ)：子公司获得甲硫酸新斯的明注射液注册证书

Core Viewpoint - Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Injection from the National Medical Products Administration, indicating a significant regulatory approval for a new product in its portfolio [1] Group 1: Product Details - Methacholine Injection is indicated for the reversal of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, treatment of myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - Methacholine is classified as a competitive acetylcholinesterase inhibitor, which works by reducing the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft to compete with non-depolarizing neuromuscular blockers [1]